Is TB-500 the same as Thymosin Beta-4?

Yes, as supplied here. Our TB-500 is full-length Thymosin Beta-4 (43 amino acids, ~4963 Da, CAS 77591-33-4), CoA-confirmed: the same molecule this study used. The actin-binding active region (around LKKTETQ) sits within that full sequence. Note that the name TB-500 is also used in the market for a short Ac-LKKTETQ fragment, which is why a CoA matters.

Was the study done in humans?

No. It is a preclinical study in mice with a corneal infection caused by Pseudomonas aeruginosa. Results from animal models cannot be transferred directly to humans.

What does this mean for TB-500 research?

It is another preclinical data point on the reparative and nerve-related mechanisms of the Tβ4 family, at a clearly defined functional endpoint. It is not evidence of any applied benefit.

Do you sell Thymosin Beta-4?

Yes. Our TB-500 is full-length 43-aa Thymosin Beta-4 (CoA-confirmed), and it is also a component of the research blends WOLVERINE (BPC-157 + TB-500) and GLOW. All for laboratory research only.

TB-500 / Thymosin Beta-4: new study on corneal nerve regeneration

Q: What was notable about the study design?

Instead of just fighting the bacteria, the authors looked at the repair that follows: visual acuity, contrast sensitivity, corneal sensitivity, and corneal nerve regeneration. Tβ4 was given as an add-on to the antibiotic Ciprofloxacin.

TL;DR: What's new

Date: June 1, 2026, Investigative Ophthalmology & Visual Science (IOVS 2026;67(6):22). Key finding: In a mouse model of bacterial corneal inflammation, Thymosin Beta-4 added on top of the antibiotic improved visual function and corneal nerve regeneration more than either treatment alone. Relevance: The study used full-length Thymosin Beta-4 (Tβ4), which is exactly the molecule supplied here as TB-500 (full-length 43-amino-acid Tβ4, CoA-confirmed), so it applies directly. The study is preclinical (animal model), with no human data.

On June 1, 2026, Investigative Ophthalmology & Visual Science published a controlled animal study from a group at Wayne State University (Detroit) titled "Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function" (Ebrahim et al., 2026, PMID 42283548).

The researchers asked whether Thymosin Beta-4 (Tβ4), added to a standard antibiotic regimen, improves healing after a corneal infection (bacterial keratitis) caused by Pseudomonas aeruginosa, with a focus on a question that is often overlooked: how well do the corneal nerves and visual function recover once the infection is gone?

What was studied

Study design

Model: C57BL/6 mice, with keratitis induced by corneal injury and inoculation with Pseudomonas aeruginosa. Treatment: Thymosin Beta-4 together with the antibiotic Ciprofloxacin, three times daily starting 24 hours after infection. Groups: control (PBS), Tβ4 alone, Ciprofloxacin alone, Tβ4 + Ciprofloxacin (adjunctive), plus non-infected controls. Endpoints: visual acuity, contrast sensitivity, corneal sensitivity, and nerve regeneration.

The approach is interesting because bacterial keratitis often leaves lasting damage even after the bacteria have been successfully cleared: a scarred cornea, reduced nerve density, and as a result diminished visual function. Antibiotics fight the infection, but they do not address the tissue repair that has to follow.

The results

The authors report that the adjunctive combination of Tβ4 and Ciprofloxacin markedly improved visual acuity and contrast sensitivity, and significantly improved corneal sensitivity and nerve regeneration, more than either treatment alone or the control.

The study's conclusion, in its own words (translated): "Adjunctive Tβ4 promotes meaningful reparative outcomes, restoring both visual function and corneal nerve integrity during P. aeruginosa keratitis."

Important: no concrete figures in the abstract

The published abstract describes the results qualitatively ("markedly", "significantly"), without exact measurements. For that reason we deliberately avoid quoting percentages here that are not supported by the source.

TB-500 and Thymosin Beta-4: the same 43-aa molecule

This is where precision matters. This study used the full Thymosin Beta-4 (Tβ4) protein, a naturally occurring regulatory protein 43 amino acids long. That is exactly the molecule we supply as TB-500: full-length 43-amino-acid Tβ4 (~4963 Da, CAS 77591-33-4), CoA-confirmed. The actin-binding active region around the LKKTETQ motif sits within that full sequence. So the findings of this study apply directly to the material sold here. Note that the name "TB-500" is also used in the market for a short Ac-LKKTETQ fragment, which is precisely why a CoA matters: ours certifies the full 43-aa form.

What this does NOT imply

The molecule matches, but an eye-infection model in mice says nothing about use in humans. The study is relevant to Tβ4/TB-500 research, not as an indication of any applied benefit.

The mechanisms described again and again for Tβ4 in the preclinical literature carry directly to the supplied material: promotion of cell migration, angiogenesis, and tissue regeneration, along with an inflammation-modulating profile. These are precisely the mechanisms cited in this corneal study to explain the observed nerve regeneration.

Context and limitations

Limitations

Animal model: mice, not a human trial. Results do not automatically transfer.
Specific disease model: bacterial keratitis, not general "healing".
Research context: all products mentioned here are intended exclusively for in-vitro laboratory research, not for use in humans or animals.

In context, the work fits into a growing body of preclinical literature describing Tβ4 as a reparative, tissue-protective signal, here extended with a clean functional endpoint (visual function and nerve density) rather than markers alone. Robust controlled human data are still lacking.

Products discussed in this study

TB-500 (full-length 43-aa Thymosin Beta-4, CoA-confirmed) is the most widely used form of Tβ4 in research. It is also a component of the combination research blends WOLVERINE and GLOW.

TB-500regeneration

Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by our CoA. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.

WOLVERINE (BPC-157 + TB-500)regeneration

The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.

GLOWregeneration

3-in-1 skin peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg. Targets collagen synthesis, tissue regeneration, and skin repair for comprehensive dermatological research.

Frequently asked questions

Source: Ebrahim AS et al. "Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function." Invest Ophthalmol Vis Sci. 2026;67(6):22. PMID 42283548.

For research purposes only. All products are sold exclusively for in-vitro laboratory research. Not for use in humans or animals, and not intended to diagnose, treat, or prevent any disease.